🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are delighted to announce Professor Karl Peggs has been appointed UCLH director of research and director of the NIHR UCLH Biomedical Research Centre. Karl, a UCLH consultant and honorary professor UCL Cancer Institute, will begin these new roles in August 2024. buff.ly/3OVPwRv

Dr Lennard Lee (Oxford University) - the overview of life sciences in the UK for cancer physicians Association of Cancer Physicians

I was overjoyed ❤️💙💚to share a stage with the amazing Heather Shaw. There was spontaneous applause when we heard what she was achieving in the #cancervaccine space! Carles Escriu, Anna Olsson-Brown Andrew Furness also showing UK cancer triumphs for the acp.org.Uk 🙂

Cancer-busting vaccines are coming: here's how they work

🏅Congratulations and well done to #teamUCLH for completing the London Landmarks Half Marathon #Marathon yesterday! 👏 Over 20 runners ran 13.1 miles past some of London's most iconic landmarks. Thank you for helping us do more for UCLH patients, staff and research. #OneTeam💙 #LLHM2024

Thank you to all at @UCLH and @MacmillanCancer for your tireless work to provide cancer patients with the best care and support.  Marking His Majesty’s return to public duties, The King and Queen spent time with patients to hear about their ongoing treatment and support.

Today, King Charles III and Queen Camilla met patients and families living with #cancer to hear their hopes and fears as they received care at our cancer centre. Thank you for taking the time to listen to our patients' experiences. Read more: buff.ly/44otiOB

It was a great honour to welcome Their Majesties to UCLH today. A wonderful opportunity to meet some of our patients and spend time with our fabulous #OneTeam staff

Inflammatory bowel disease (#IBD) increases bowel cancer risk: 1/3 of patients with low grade dysplasia (LGD) will get cancer. This risk is very high &reason for treatment. But also major conundrum b/c 2/3 patients with LGD won't get cancer. Can we know who is really at risk? 1/3

We found that measurement (by lpWGS) of aneuploidy in LGD (burden & specific genetic alterations) very strongly predicts bowel cancer risk: >90% accurate over 5 years. We think the test is good enough (& cheap & easy enough) to be evaluated for clinical use in years ahead. [2/3]

Preprint is here: medrxiv.org/content/10.110… Many years work by many amazing people (including): Ibrahim AlBaker Kit Curtius George Cresswell Nadia Nasreddin salpie nowinski Ailsa Hart Simon Leedham St Mark's Hospital Foundation The ICR [3/3]

Yet more evidence that somatic copy number alterations define the malignant transition in many carcinomas - this time in CRC from IBD. Love to know the underlying biology!

Thrilled to share our discovery of novel long-deletion #signatures—powerful markers for tracking #MMRd #CancerEvolution, even in low-pass (~0.1X) FFPE samples with low tumour content, using our tool #MILO. Check out our preprint for the full story biorxiv.org/content/10.110… (1/8)

Very pleased to see our work with J Richter, D Isenberg and Claire Roddie published in Bone Marrow Transplantation nature.com/articles/s4140… 1/CAR-T cell therapy, is making strides in treating autoimmune diseases and may be the future of treating such conditions Let’s dive in

A pan-cancer single-cell RNA-seq atlas of intratumoral B cells dlvr.it/TFNVLL

CD19 CAR-T is safe and effective for intra-cardiac NHL. Key to this is multidisciplinary care with cardio-oncology colleagues. ⁦Nice piece led by Dan Chen, ⁦Dr Arjun Ghosh (London Cardio-Oncology)⁩ Kathleen Cheok⁩ ⁦Maeve O'Reilly⁩ ⁦UCLH⁩ ⁦UCL Cancer Institute⁩ onlinelibrary.wiley.com/doi/10.1002/jh…

thelancet.com/journals/lanha… Happy to share 15 year follow-up of our study of early rituximab vs watchful waiting for advanced stage, asymptomatic, low tumour burden FL. Substantial delay in TTNT highlights the value of early R for pts seeking to defer/avoid chemo. #lymsm #lymphoma

Newly reported updated results of a study from UCLH and UCL highlights the powerful benefits of a targeted immune therapy for a type of slow-growing blood cancer. Find out more: buff.ly/Pe9KcVA #Lymphoma

Great opportunity to work with myself, Claire Roddie Maeve O'Reilly Paul Maciocia and Maise Al Bakir in our UCLH cellular therapy team go gain experience of delivering standard of care CAR T and trials in solid onc and AID. uclh.nhs.uk/work-with-us/c…

CAR-T Fellow post available UCLH. Application deadline 04/06/2025. Working with the fabulous Claire Roddie Maeve O'Reilly Paul Maciocia Mike Northend uclh.nhs.uk/work-with-us/c…